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(57) ABSTRACT 
This invention relates to a chemical compound that inhibits 
the apoptotic activity of the protease Omi/HtrA2 and 
homologous proteins. This protease Omi/HtrA2 is present in 
all mammalian cells so that inhibition of apoptosis in this 
fashion results enhanced cellular health and therapeutic 
effects. 
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METHOD AND COMPOUND FOR 
INHIBITION OF CELL DEATH 
This invention relates to a protease and more particular to 
a chemical compound that inhibits the apoptotic activity of 
the protease Omi/HtrA2, and method for using such com-
pound for therapeutic use. 
BACKGROUND AND PRIOR ART 
2 
cades, in which caspases activate themselves and each other. 
Within these cascades, caspases can be positioned as down-
stream effectors of apoptosis. 
U.S. Pat. No. 6,004,794 discloses isolated nucleic acids 
encoding a human serine protease PSPI, protein obtainable 
from the nucleic acids, recombinant host cells transformed 
with the nucleic acids, oligonucleotides and primer pairs 
specific for PSPl polymorphisms and use of the protein and 
nucleic acid sequences. This patent thus discloses the Omi/ 
10 HtrA2 which has been identified as a mitochondrial apop-
totic serine protease that also disrupts the inhibition of 
apoptosis protein-caspase interaction. 
Many of today's medical diseases can be attributed 
directly or indirectly to problems with apoptosis-a pro-
grammed cell-suicide mechanism. Disorders in which defec-
tive regulation of apoptosis contributes to disease pathogen-
esis or progression can involve either cell accumulation, in 
which cell eradication or cell turnover is impaired, or cell 
loss, in which the cell-suicide program is inappropriately 
triggered. Identification of the genes and gene products that 
are responsible for apoptosis, together with emerging infor-
mation about the mechanisms of action and structures of 20 
apoptotic regulatory and effector proteins, has laid a foun-
dation for the discovery of drugs, some of which are now 
undergoing evaluation in human clinical trials. 
Since the Omi/HtrA2 is present in all mammalian cells 
and by its activity of disrupting the inhibition of the "apo-
15 ptosis protein-caspase interaction" decreases the cell life-
time, it would be most important to discover an inhibitor of 
the adverse activity ofOmi/HtrA2 and homologous proteins. 
Typically, one thinks of cell death as being a pathological 25 
phenomenon, but in fact, each second nearly one million 
cells commit suicide in the adult human body. In an average 
day, we produce, and in parallel eradicate, -60xl09 cells 
which represents a mass of cells equivalent to an entire body 
weight on an annual basis. This massive flux of cell birth and 30 
death occurs in the self-renewing tissues of the body (skin, 
gut, bone marrow and sex organs), providing mechanisms 
for rapidly regulating cell numbers by controlling the rates 
of both input and elimination. Physiological cell death has 
important roles in a wide variety of normal processes, 35 
ranging from fetal development to ageing, and including: 
immune system education, for which potentially autoreac-
tive cells are eliminated; defense against viruses, for which 
altruistic cell suicide can deny viral replication within a host; 
tissue homeostasis, for which cell production is offset by 40 
commensurate cell eradication, thereby ensuring appropriate 
total cell numbers in vivo; and many aspects ofreproductive 
biology. 
Programmed cell death is vital to the existence of virtually 
all organisms, As a result, knowledge about programmed 45 
cell-suicide mechanisms can have broad ramifications for 
devising strategies for protecting crops, interfering with 
insect and parasite life cycles, tissue engineering and ex vivo 
cell production, and the development of human therapeutics. 
Physiological or programmed cell death generally occurs by 50 
apoptosis and defects in the physiological pathways for 
apoptosis have a role in many diseases. A reasonable esti-
mate is that either too little or too much cell death contrib-
utes to half of the main medical illnesses for which adequate 
therapy or prevention is lacking. Consequently, great interest 55 
has emerged in devising therapeutic strategies for modulat-
ing the key molecules that make life-or-death decisions in 
cells. 
SUMMARY OF THE INVENTION 
The first objective of the present invention is to discover 
one or more inhibitors of Omi/HtrA2. 
The second objective of the invention is to identify an 
inhibitor of Omi/HtrA2 which reduces the inhibition of the 
cellular apoptosis protein-caspase interaction. 
The third objective of the invention is to discover an 
inhibitor of L56 protein. 
The fourth objective of the invention is to discover an 
inhibitor of bacterial HtrA. 
The fifth objective of the invention is to provide a method 
for screening for compounds which inhibit apoptosis. 
The sixth objective of the invention is to provide a method 
for screening for compounds which inhibit Omi/HtrA2. 
The preferred embodiments of invention identifies a 
chemical inhibitor of Omi/HtrA2 whose structure is 
0 
// 
o--N+ 
and its use in the inhibition of excessive mammalian 
apoptosis. 
Further objects and advantages of this invention will be 
apparent from the following detailed description of the 
presently preferred embodiments. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
Before explaining the disclosed embodiment of the 
60 present invention in detail, it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangement shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
Apoptosis is generally caused by proteases known as 
"caspases". Caspases constitute a family of intracellular 
cysteine proteases that cleave substrates at aspartic acid 
(Asp) residues. Produced initially as inactive zygomens, 
caspases are triggered into action generally as a result of 
their proteolytic processing at conserved Asp residues. 
Because caspases both cleave their substrates at Asp resi- 65 
dues and are also activated by proteolytic processing at Asp 
residues, these proteases can collaborate in proteolytic cas-
for the purpose of description and not of limitation. 
It would be useful to discuss the meanings of some words 
used herein and their applications before discussing the 
novel compound of the invention and its inhibition activity: 
US 7,288,546 Bl 
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apoptosis-an active process of programmed cell death 
characterized by distinct morphological changes in the cell 
caspases-a family of intracellular cysteine proteases that 
generally are responsible for apoptosis; 
inhibitor of apoptosis protein (IAP)-contains at least one 
copy of Baculovirus IAP of a repeat (BIR) domain and 
suppresses apoptosis when overexpressed and is known to 
bind and inhibit caspases; 
zymogen-the inactive proform of an enzyme which is 
typically activated by proteolysis 
The invention as noted from the prior art is concerned 
basically with the discovery that the activity of Omi/HtrA2 
and homologous proteins are inhibited by a compound of the 
structure 
0 
// 
o--w 
This structure, whose chemical name is 5-{ 5-(2-nitro-phe-
ny 1)-furan-2-y lmethy lene }-1,3-dipheny 1-2-thioxo-dihydro-
pyrimidine-4, 6-dione will hereinafter be referred to as UCF 
101. 
4 
allograft rejection and graft versus host disease; 
type 1 diabetes; and, 
trauma (spinal-cord injury, brain injury). 
EXAMPLE 1 
Omi shows proteolytic activity in the following assay that 
uses ~-casein as a generic substrate. 528 compounds were 
10 
screened for inhibition of this assay, and the sole compound 
which resulted in inhibited activity was UCF 101: 
Preparation of FITC-Labeled Unphosphorylated Casein 
(FITC-Casein). FITC (Fluorescein Isothiocyanate ), 3 7 .5 mg, 
15 was dissolved in 2.5 ml DMSO. 1.6 ml of this FITC solution 
was added with stirring to 800 ml Borate buffer (50 mM 
Sodium Borate, pH 9.3, 40 mM NaCl) to make a final 
solution of 0.03 mg FITC/ml. 3 ml of casein (2 mg/ml) was 
20 
placed in "A Slide-A-Lyzer" Dialysis Cassettes (Pierce, Ill.) 
and then placed in freshly prepared labeling solution (Borate 
buffer and FITC), covered with aluminum foil and left at 4 ° 
C. for 2 days with continuous stirring. After labeling, the "A 
Slide-A-Lyzer" cassette was placed in dialysis buffer (50 
25 mM Tris-HCl, pH7.5 and 50 mM NaCl) for four days at 40 
C with stirring to remove uncoupled FITC. After this time 
the casein-FITC conjugate was removed and stored at -20° 
C. in the dark. 
Protease assay using MBP-Omi134_458 and FITC-casein. 
30 Opaque microtiter plates were used to minimize background 
and assays were always performed in duplicate. In a typical 
assay, approximately 10 µg (50 µl) FITC-casein solution was 
placed in each well of a microtiter plate well using Multi-
drop 384 multiple dispenser (Labsystems), and incubated in 
35 the Wallac 1420 Victor2 Multilabel Counter at 37° C. for 15 Moreover, Omi/HtrA2 also has homology with other 
cellular proteins, such as L56, another mammalian protein, 
and bacterial HtrA at the carboxyl terminus of the polypep-
tides. Thus inhibition of these proteins with UCF 101 is also 
indicated. While Om/HtrA2 is sequestered primarily in the 
mitochondria, L56 is not and therefore may be even more 40 
susceptible to inhibition. L56 has been shown to be differ-
entially expressed in human osteoarthritic cartilage. Further, 
bacteria which lack HtrA are less virulent and thus inhibition 
minutes. After this time 50 µl (2 µg) of MBP-Omi134_458 in 
100 µl of assay buffer (20 mM Sodium Phosphate, pH7.5, 
200 mM NaCl, 5% Glycerol) were added. After one minute 
delay, the fluorescence change was read every 5 minutes 
during 30 minutes at 535 nm. The relative rate for each 
reaction was calculated using the fluorescence change in the 
initial 20 minutes after subtracting the blank values (no 
MBP-Omi134-4ss)-
by UCF 101 effectively results in its use as an antibiotic. Synthesis and purification of MBP-Omi134_458. 
By targeting the caspase directly by inhibiting the Omi/ 45 
Htr/A2 activity which reduces the inhibition of the cellular 
apoptosis protein-caspase interaction, or by virtue of its 
serine-protease activity the following applications of the 
invention are prospectively useful when excessive apoptosis 
in a human is present: 50 
pMAL-c2 prokaryotic expression vector (New England 
Biolabs) was used to express f MBP-Omi134_458 . DNA 
primers were designed to PCR amplify the DNA sequence 
corresponding to amino acids 134 to 458. The PCR fragment 
was cloned into pMAL-c2 to express the Omi134_458 as a 
fusion with MBP. The recombinant protease was purified on 
a Maltose-binding affinity column following a standard 
protocol (NEB). The concentration of fusion protein was 
determined using the Bradford assay. Integrity and purity of 
ischemia-reperfusion injury (stroke, myocardial infarction). 
In addition to apoptotic cell death, necrosis is also present; 
heart failure-(loss of myocardiocytes); 
neuro-degeneration-(Alzheimer's disease, Parkinson's 
disease, Hntington's disease and amytrophic lateral sclero-
sis); 
inflammation; 
osteoarthritis; 
human immunodeficiency virus-(loss of T lymphocytes); 
bacterial infection-apoptosis-inducing virulence proteins 
are secreted into the cytosol of host cell. (Examples are 
Shigella spp, Salmonella spp, Yersinia spp and Chlamydia 
spp.); 
55 the protein was assessed by SDS-PAGE. 
Combinatorial library screening. Six plates of Pharma 
Library Collection (Nanosyn, Inc, Calif.) representing a total 
of 528 compounds were screened for inhibition of the 
proteolytic activity ofMBP-Omi134_458 . 58 µl ofDMSO was 
60 added to each well containing 30 nmole of a compound (2 
µl) to make 500 µM final solution. 2 µl of each of the 
compounds was added per well in a microtiter plate fol-
lowed by 50 µl of a FITC-casein solution (10 ug); after 15 
min. preincubation at 370 C, 50 µl of MBP-Omi134_458 . (2 
65 ug) protease was added. After one minute delay, fluores-
cence change was monitored every 5 minutes for 30 minutes 
at 535 nm. 
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EXAMPLE 2 
study using ucf-101 inhibitor to block apoptosis. 
Mouse embryo fibroblasts caspase-9-/- were transfected 
with pEGFP-Nl as control and M-Omi-GFP, in pres-
ence or absence ofucf-101 at increasing concentration 
(5 to 25 µM). The percentage of apoptotic cells were 
determined using propidium iodide and 4',6'-diami-
dino-2-phenylindole stains. Normal and apoptotic 
10 GFP-expressing cells were counted using fluorescence 
microscopy. Transfected cells treated with inhibitor 
ucf-101 showed decreased apoptosis 
HeLa cells were transfected with mature Omi (aa134-
458), Omi-AVPS-GFP and mature Omi where the first 
15 Alanine (A) was mutated to a Glycine. Omi-GVPS-GFP 
transfected cells were treated with increasing concentration 
ofucf-101. Overexpression of mature Omi-GVPS-GFP can 
induce apoptosis only through its ability to function as an 
active protease (caspase-independent pathway). Using ucf-
20 101 we were able to inhibit its protease activity and apop-
tosis. 
UCF-101 was purchased from Nanosyn (Nonoscale 
Cominatorial Synthesis Inc., 625 Clyde Ave, Mountain 
View, Calif. 94943-2213 
25 While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope 
of the invention is not intended to be, nor should it be 
deemed to be, limited thereby and such other modifications 
or embodiments as may be suggested by the teachings herein 
6 
are particularly reserved especially as they fall within the 
breadth and scope of the claims here appended. 
I claim: 
1. A method of inhibiting a protein selected from the 
group consisting of Omi/HtrA2, L56, and bacterial HtrA 
comprising reacting the protein with a compound of the 
formula 
0 
// 
o--w 
2. A method, as in claim 1, wherein said protein is protein 
L56. 
3. An method, as in claim 1, wherein said protein is 
bacterial HtrA. 
4. A method, as in claim 1, wherein said protein is 
Omi/HtrA2. 
* * * * * 
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